Surmodics Inc SRDX
We take great care to ensure that the data presented and summarized in this overview for SURMODICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SRDX
View all-
Black Rock Inc. New York, NY1.17MShares$46.4 Million0.0% of portfolio
-
Alliancebernstein L.P. New York, NY1.04MShares$41.2 Million0.01% of portfolio
-
Beryl Capital Management LLC Redondo Beach, CA989KShares$39.2 Million14.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA804KShares$31.8 Million0.0% of portfolio
-
Morgan Stanley New York, NY753KShares$29.8 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT638KShares$25.3 Million2.1% of portfolio
-
Trigran Investments, Inc.543KShares$21.5 Million2.31% of portfolio
-
Qube Research & Technologies LTD London, X0404KShares$16 Million0.02% of portfolio
-
Dimensional Fund Advisors LP Austin, TX380KShares$15.1 Million0.0% of portfolio
-
State Street Corp Boston, MA374KShares$14.8 Million0.0% of portfolio
Latest Institutional Activity in SRDX
Top Purchases
Top Sells
About SRDX
Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The IVD segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Insider Transactions at SRDX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 26
2024
|
Timothy J. Arens Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,009
-9.06%
|
$273,351
$39.44 P/Share
|
Aug 21
2024
|
Gary R Maharaj President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
50,569
-19.98%
|
$2,022,760
$40.06 P/Share
|
Aug 21
2024
|
Gary R Maharaj President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
61,017
+19.42%
|
$2,013,561
$33.2 P/Share
|
Aug 21
2024
|
Joseph J. Stich SVP of HR, President IVD |
SELL
Payment of exercise price or tax liability
|
Direct |
19,434
-23.3%
|
$777,360
$40.06 P/Share
|
Aug 21
2024
|
Joseph J. Stich SVP of HR, President IVD |
BUY
Exercise of conversion of derivative security
|
Direct |
21,285
+20.33%
|
$702,405
$33.2 P/Share
|
Aug 16
2024
|
Timothy J. Arens Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,729
-17.78%
|
$669,160
$40.06 P/Share
|
Aug 16
2024
|
Timothy J. Arens Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,447
+16.39%
|
$608,751
$33.2 P/Share
|
Aug 16
2024
|
Charles W Olson SVP, Medical Device Coatings |
SELL
Payment of exercise price or tax liability
|
Direct |
16,727
-23.66%
|
$669,080
$40.06 P/Share
|
Aug 16
2024
|
Charles W Olson SVP, Medical Device Coatings |
BUY
Exercise of conversion of derivative security
|
Direct |
18,447
+20.69%
|
$608,751
$33.2 P/Share
|
Feb 08
2024
|
David Dantzker |
BUY
Grant, award, or other acquisition
|
Direct |
1,803
+4.41%
|
-
|
Feb 08
2024
|
Jose H Bedoya |
BUY
Grant, award, or other acquisition
|
Direct |
1,803
+5.86%
|
-
|
Feb 08
2024
|
Jose H Bedoya |
SELL
Payment of exercise price or tax liability
|
Direct |
2,954
-9.81%
|
$91,574
$31.89 P/Share
|
Feb 08
2024
|
Jose H Bedoya |
BUY
Exercise of conversion of derivative security
|
Direct |
3,932
+11.55%
|
$90,436
$23.95 P/Share
|
Feb 08
2024
|
Susan E Knight |
BUY
Grant, award, or other acquisition
|
Direct |
1,944
+5.24%
|
-
|
Feb 08
2024
|
Ronald B Sr Kalich |
BUY
Grant, award, or other acquisition
|
Direct |
1,803
+4.5%
|
-
|
Feb 08
2024
|
Lisa Wipperman Heine |
BUY
Grant, award, or other acquisition
|
Direct |
1,803
+11.82%
|
-
|
Feb 05
2024
|
Susan E Knight |
SELL
Payment of exercise price or tax liability
|
Direct |
3,063
-8.45%
|
$91,890
$30.75 P/Share
|
Feb 05
2024
|
Susan E Knight |
BUY
Exercise of conversion of derivative security
|
Direct |
3,932
+9.78%
|
$90,436
$23.95 P/Share
|
Jan 19
2024
|
David Dantzker |
SELL
Payment of exercise price or tax liability
|
Direct |
2,773
-6.92%
|
$91,509
$33.97 P/Share
|
Jan 19
2024
|
David Dantzker |
BUY
Exercise of conversion of derivative security
|
Direct |
3,932
+8.93%
|
$90,436
$23.95 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 75.8K shares |
---|---|
Exercise of conversion of derivative security | 135K shares |
Payment of exercise price or tax liability | 115K shares |
---|---|
Open market or private sale | 7.01K shares |